Evaxion A/S (EVAX) Stock: Buy, Sell, or Hold?
EVAX - Evaxion A/S American Depositary Share
$3.13
0.03 (0.97%)
â˛
5d:
+1.62%
30d:
+1.95%
90d:
-13.3%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When EVAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: EVAX is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: EVAX is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: EVAX is currently trading at $3.13, which is considered fair relative to its 30-day fair value range of $3.03 to $3.26. From a valuation perspective, the stock is trading at a discount (Forward PE: -208.7) compared to its historical average (83.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, EVAX is in a strong downtrend. Immediate support is located at $2.90, while resistance sits at $3.33.
Market Sentiment: EVAX scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.25 (+259.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EVAX is in a strong downtrend. Immediate support is located at $2.90, while resistance sits at $3.33.
Market Sentiment: EVAX scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.25 (+259.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.03 -
$3.26
Company Quality Score
36/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (36/100)
- BULLISH: Trading 259.4% below Wall St target ($11.25)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 36/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.03 -
$3.26
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.90
Resistance Level
$3.33
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-208.67
Wall Street Target
$11.25
(+259.4%)
Revenue Growth (YoY)
-100.0%
Profit Margin
-115.5%
PE vs Historical
-208.7 vs 83.6
CHEAP
Share & Embed Analysis
Last updated: September 13, 2026 6:59 PM ET
Data refreshes hourly during market hours. Next update: 7:59 PM
Data refreshes hourly during market hours. Next update: 7:59 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$569 | 38 SELL |
|
CRNX
Crinetics PharmaceuticalâĻ |
STRONG BUY
17 analysts |
$86 | 46 HOLD |